LIANY: AI 评分 51/100 — AI 分析 (4月 2026)

LianBio is a biopharmaceutical company focused on developing and commercializing innovative medicines in China and other Asian markets. The company targets cardiovascular, oncology, ophthalmology, and inflammatory diseases.

Key Facts: Price: $0.14 AI Score: 51/100 Sector: Healthcare

公司概况

概要：

LianBio is a biopharmaceutical company focused on licensing and developing therapeutics for cardiovascular, oncology, ophthalmology, and inflammatory diseases in China and other Asian markets, facing the challenges of regulatory hurdles and market access while offering a high dividend yield of 260.61% and operating with a beta of 0.42.

LIANY是做什么的？

LianBio, incorporated in 2019 and headquartered in Princeton, New Jersey, is a biopharmaceutical company dedicated to bringing innovative medicines to patients in China and other Asian markets. The company focuses on in-licensing and developing therapies for significant unmet medical needs across cardiovascular, oncology, ophthalmology, and inflammatory diseases. LianBio's pipeline includes mavacamten for hypertrophic cardiomyopathy and heart failure, TP-03 for Demodex blepharitis and meibomian gland disease, NBTXR3 for head and neck squamous cell carcinoma and solid tumors, Infigratinib for cholangiocarcinoma and gastric cancers, BBP-398 for solid tumors, Omilancor and NX-13 for ulcerative colitis and Crohn's disease, LYR-210 for chronic rhinosinusitis, and Sisunatovir for respiratory syncytial virus. LianBio has established strategic partnerships with companies like Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 and Nanobiotix S.A. to develop and commercialize NBTXR3. The company aims to address critical healthcare needs in its target markets by leveraging its expertise in clinical development and regulatory affairs.

LIANY的投资论点是什么？

LianBio presents a high-risk, high-reward investment opportunity. The company's strategy of in-licensing and developing drugs for the Chinese and Asian markets offers significant potential, given the large patient populations and unmet medical needs. Key value drivers include successful clinical trials and regulatory approvals for its pipeline assets, particularly mavacamten, TP-03, and NBTXR3. The company's current P/E ratio is 7.21, and the dividend yield is 260.61%. However, investors should be aware of the risks associated with drug development, regulatory hurdles, and market access in China. The company's relatively small market cap of $0.02 billion also introduces volatility. Upcoming clinical trial results and regulatory decisions will be critical catalysts for the stock.

LIANY在哪个行业运营？

LianBio operates in the competitive biotechnology industry, characterized by high R&D costs, lengthy development timelines, and regulatory scrutiny. The company focuses on the Chinese and Asian markets, which are experiencing rapid growth in healthcare spending and demand for innovative medicines. Key trends include increasing regulatory reforms to accelerate drug approvals and growing investment in local biotech companies. LianBio competes with both multinational pharmaceutical companies and local Chinese players. Competitors include companies like CHMMF and CUBT, which are also developing and marketing pharmaceutical products.

Biotechnology

Healthcare

LIANY有哪些增长机遇？

Expansion of Mavacamten: Mavacamten, targeting obstructive and non-obstructive hypertrophic cardiomyopathy, represents a significant growth opportunity. The global market for heart failure therapeutics is projected to reach $16.5 billion by 2028. Successful clinical trials and regulatory approval in China could drive substantial revenue growth for LianBio. The timeline for approval is dependent on ongoing trials and regulatory review processes.
Commercialization of TP-03: TP-03, for the treatment of Demodex blepharitis, offers a targeted growth opportunity in the ophthalmology space. The global blepharitis market is expected to reach $640 million by 2027. LianBio's partnership with Tarsus Pharmaceuticals provides a strong foundation for commercialization in China. Regulatory approval and successful market penetration are key to realizing this growth potential.
Development of NBTXR3: NBTXR3, a radioenhancer for head and neck squamous cell carcinoma and solid tumors, presents a significant growth opportunity in oncology. The global market for cancer therapeutics is projected to reach $286 billion by 2025. Successful clinical trials and regulatory approval could position NBTXR3 as a valuable addition to cancer treatment regimens. LianBio's partnership with Nanobiotix S.A. is crucial for this development.
Advancement of Infigratinib: Infigratinib, targeting cholangiocarcinoma and gastric cancers, represents a strategic growth opportunity in oncology. The global market for cholangiocarcinoma therapeutics is growing due to increasing incidence rates. Successful clinical trials and regulatory approval in China could drive significant revenue growth for LianBio. The timeline for approval is dependent on ongoing trials and regulatory review processes.
Pipeline Expansion: LianBio's pipeline of other drugs, including BBP-398, Omilancor, NX-13, LYR-210 and Sisunatovir, provides multiple avenues for future growth. Each of these drugs targets specific unmet medical needs in large patient populations. Successful clinical development and regulatory approval could contribute significantly to LianBio's long-term growth prospects. The timeline for approval is dependent on ongoing trials and regulatory review processes.

Market capitalization of $0.02 billion indicates a small-cap company with potential for high growth but also higher volatility.
P/E ratio of 7.21 suggests the company may be undervalued compared to its earnings, but this should be considered in the context of its growth stage and risks.
Dividend yield of 260.61% is exceptionally high and may not be sustainable, warranting further investigation into the company's financial stability and dividend policy.
Beta of 0.42 indicates the stock is less volatile than the market, which may appeal to risk-averse investors.
Focus on the Chinese and Asian markets provides access to large patient populations and potential for significant revenue growth if key drugs are approved and commercialized successfully.

LIANY提供哪些产品和服务？

Develop and commercialize medicines for cardiovascular diseases.
Focus on oncology therapeutics for various types of cancers.
Address ophthalmological conditions like Demodex blepharitis.
Develop treatments for inflammatory diseases such as ulcerative colitis and Crohn's disease.
Target the Chinese and other Asian pharmaceutical markets.
Partner with international pharmaceutical companies to in-license drug candidates.
Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.

LIANY如何赚钱？

In-licensing drug candidates from other pharmaceutical companies.
Developing and conducting clinical trials for these drug candidates.
Seeking regulatory approval for their drugs in China and other Asian markets.
Commercializing and marketing their approved drugs in these markets.

Patients in China and other Asian countries suffering from cardiovascular diseases.
Patients with various types of cancer, including cholangiocarcinoma and gastric cancers.
Individuals suffering from ophthalmological conditions like Demodex blepharitis.
Patients with inflammatory diseases such as ulcerative colitis and Crohn's disease.

Strategic partnerships with international pharmaceutical companies provide access to innovative drug candidates.
Focus on the Chinese and Asian markets allows them to address specific unmet medical needs in these regions.
Expertise in clinical development and regulatory affairs helps them navigate the complex drug approval process.
Diversified pipeline of drug candidates targeting multiple therapeutic areas reduces reliance on any single product.

什么因素可能推动LIANY股价上涨？

Upcoming: Clinical trial results for Mavacamten in hypertrophic cardiomyopathy.
Upcoming: Regulatory approval decisions for TP-03 in Demodex blepharitis.
Upcoming: Clinical trial data releases for NBTXR3 in head and neck squamous cell carcinoma.
Ongoing: Expansion of partnerships to broaden the pipeline of drug candidates.
Ongoing: Advancements in regulatory reforms in China to accelerate drug approvals.

LIANY的主要风险是什么？

Potential: Unsuccessful clinical trials for key drug candidates.
Potential: Regulatory setbacks or delays in drug approvals in China and other Asian countries.
Potential: Competition from larger pharmaceutical companies with greater resources.
Ongoing: High R&D costs and long development timelines associated with drug development.
Ongoing: Dependence on in-licensing drug candidates, which can be subject to availability and competition.

LIANY的核心优势是什么？

Strong pipeline of drug candidates targeting multiple therapeutic areas.
Strategic partnerships with international pharmaceutical companies.
Focus on the high-growth Chinese and Asian pharmaceutical markets.
Experienced management team with expertise in clinical development and regulatory affairs.

LIANY的劣势是什么？

Reliance on in-licensing drug candidates, which can be subject to availability and competition.
High R&D costs and long development timelines associated with drug development.
Regulatory hurdles and market access challenges in China and other Asian countries.
Small market capitalization and limited financial resources compared to larger pharmaceutical companies.

LIANY有哪些机遇？

Expanding their pipeline through additional in-licensing agreements.
Accelerating the development and approval of their existing drug candidates.
Expanding their geographic reach within China and other Asian markets.
Leveraging their expertise to develop novel drug candidates in-house.

LIANY面临哪些威胁？

Competition from larger pharmaceutical companies with greater resources.
Unsuccessful clinical trials or regulatory setbacks for their drug candidates.
Changes in regulatory policies or market conditions in China and other Asian countries.
Intellectual property disputes or challenges to their patent protection.

LIANY的竞争对手是谁？

Bayer AG — Multinational pharmaceutical and life sciences company. — (BETRF)
ChromaDex Corp — Focuses on nutraceuticals and dietary supplements. — (CHMMF)
Cubist Pharmaceuticals — Specializes in antibiotics and anti-infectives (now part of Merck). — (CUBT)
IntriCon Corporation — Designs and manufactures miniature and micro-acoustic products. — (INTI)
Oxford Biomedica plc — Gene and cell therapy company. — (OXBOF)

Key Metrics

Price: $0.14 (-20.81%)
Market Cap: $16.0M
P/E Ratio: 6.12
MoonshotScore: 51/100

Company Profile

CEO: Adam Leo Stone
Headquarters: Princeton, US
Employees: 163
Founded: 2021

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does LianBio do?

LianBio is a biopharmaceutical company focused on identifying, developing, and commercializing innovative medicines for unmet medical needs in China and other Asian markets. The company in-licenses promising drug candidates from Western pharmaceutical companies and advances them through clinical development and regulatory approval in its target markets. LianBio's pipeline targets cardiovascular, oncology, ophthalmology, and inflammatory diseases, leveraging strategic partnerships to bring novel therapies to patients in Asia.

What do analysts say about LIANY stock?

Analyst coverage of LIANY stock is limited due to its small market capitalization and OTC listing. Key valuation metrics, such as P/E ratio and dividend yield, should be interpreted cautiously given the company's growth stage and inherent risks. Growth considerations include successful clinical trial outcomes, regulatory approvals, and market penetration in China and other Asian countries. Analyst consensus is not readily available, and investors should conduct their own thorough research before making investment decisions. No buy/sell recommendations are available.

What are the main risks for LIANY?

The main risks for LianBio include the inherent uncertainties of drug development, such as unsuccessful clinical trials and regulatory setbacks. The company also faces competition from larger pharmaceutical companies and challenges associated with market access in China and other Asian countries. Dependence on in-licensing drug candidates exposes LianBio to the risk of losing access to key assets. The company's OTC listing and small market capitalization contribute to increased volatility and liquidity risks. Investors should carefully consider these risks before investing.